The Research and Technology Vice Chancellorship at Tehran University of Medical Sciences (TUMS) is driving technological advancement through extra-academic research. Dr. Bahareh Yazdizadeh, Director of Research and Technology Affairs, outlined three impact tiers: (A) Knowledge-based product development, (B) Research implementation, and (C) Health, social, and economic benefits. One major project is the ProSpect cardiac SPECT device, with insights from Dr. Mohammad Reza Ay, head of the preclinical lab. Additionally, Dr. Ay introduced software for high-resolution imaging in the Xtrim PET system, enhancing drug research. Further innovations include the production of "Faxibet Plus" and "Tofaxel" by Noavaran Daroui Kimia Company, with Dr. Zahra Rezaei detailing their development. These initiatives reinforce TUMS’s commitment to research-driven technological progress.